PharmaTelevision - Nicast’s New Application of an Old Technology

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Nicast’s New Application of an Old Technology

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview Jacob Dagan, Chairman of the Board of Nicast, talks Fintan Walton through the company’s unique application of electrospinning. This technology was first discovered sixty years ago and Nicast has taken it on to create specific materials that can fill unmet medical needs. With the help of an animated video, Mr. Dagan describes exactly how the materials can be used to the benefit of the patient. Nicast plans to develop these products and only partner them at a late stage for help with marketing and commercialisation.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Founding of Nicast and its technology.

Fintan Walton:

Hello and welcome to PharmaVentures business review here in San Francisco. On this show I have Jacob Dagan who is the chairman of a company called Nicast which is based in Israel. Welcome to the show.

Jacob Dagan:

Thank you.

Fintan Walton:

Jacob Dagan you head up a company which is a medical device company that's the one we are describing it. It's got some very unique technology which has potential applications in a wide range of medical uses. First of all just tell us what the basis of the company is and the technology and how it was founded.

Jacob Dagan:

Okay. We are using a technology that is called electrospinning. It's of quite an old technology was discovered some sixty years ago in this country and it was really put into use by the Russians later and they used it for manufacturing of different materials specially for welfare and production of different kinds of filters that would stop the movement of different or transfer of different agents. Some sixteen seventeen years ago an immigrant from Russia Dr. Alex Dobson came to Israel. It was a very deep knowledge of this technology and he came with the notion that he would like to start a business where he would develop a filter material for vapor filters you know those filters which are used in the pharmaceutical industry and got funded by the chief scientists in Israel and for two years and developed the machine quite a big machine that can produce filters and then the project went into they re-evolved they had to build a machine that can develop and manufacture this in big quantities, realized that building such a machine that can really supply the needs of the market the price of the machine is around $25 million dollars. We are talking about big machines

Fintan Walton:

Right.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Jacob Dagan

Chairman of the Board

Dr. Jacob Dagan, Chairman of the Board of Nicast, has more than 20 years experience in a wide range of medical device industries, and is the founder of numerous medical device companies launched in the US. Dr. Jacob Dagan earned a DSc & Eng. in biomedical engineering from Columbia University, New York.

Nicast

Nicast Ltd. is a pioneer in the development of implantable medical devices made of electrospun polymer nanofabrics for a wide range of applications. The company's first two products, the AVflo vascular access graft and NovaMesh demonstrate the versatility of electrospun nanofabric as a biomaterial from which medical devices with superior properties can be made. The AVflo is intended for patients with end stage renal failure (kidney failure) who must undergo hemodialysis treatment. The NovaMesh is intended to repair ventral(abdominal)hernias. These products address a combined global market of $0.7 billion to $1 billion. Nicast has long identified the significant potential of electrospinning technology and biomaterials and has been working to apply this technology to a wide range of medical applications. Nicast has six patents in the US, nine patents outside of the US and 14 additional patents pending.